
    
      A phase III clinical study on efficacy and safety of SHR3824 combined with metformin for type
      2 diabetes with poor glucose control in metformin monotherapy (multicenter, randomized,
      double-blind, placebo-parallel control). The 450 subjects received at least eight weeks of
      metformin monotherapy at a steady dose of 1500 mg or more before screening.

      Evaluation of efficacy: compared with the group of placebo combined with metformin, HbA1c,
      fasting plasma glucose, postprandial plasma glucose, fasting body weight and blood pressure
      changes in the SHR3824 with metformin group
    
  